{"url_path":"/sec/crdf/8-k/2026-08-11/item-2-02","section_key":"item-2-02","section_title":"Item 2.02 Results of Operations and Financial Condition.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-08-11","source_url":"https://www.sec.gov/Archives/edgar/data/1213037/0001193125-26-344645-index.html","accession_number":"0001193125-26-344645","cik":"0001213037","ticker":"CRDF","issuer_name":"Cardiff Oncology, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1213037/0001193125-26-344645-index.html","primary_entity_key":"0001213037","primary_entity_name":"Cardiff Oncology, Inc."},"word_count":49,"has_tables":true,"body_markdown":"## Item 2.02 Results of Operations and Financial Condition.\n\nOn August 11, 2026, Cardiff Oncology, Inc. issued a press release announcing a business update and financial results for the second quarter ended June 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K."}